(Q36644307)

15 August 2017

The level of haemoglobin in anaemic cancer patients correlates positively with quality of life (English)

1 reference

15 August 2017

1 reference

M Lind

1

1 reference

15 August 2017

C Vernon

2

1 reference

15 August 2017

D Cruickshank

3

1 reference

15 August 2017

P Wilkinson

4

1 reference

15 August 2017

T Littlewood

5

1 reference

15 August 2017

N Stuart

6

1 reference

15 August 2017

C Jenkinson

7

1 reference

15 August 2017

P Grey-Amante

8

1 reference

15 August 2017

H Doll

9

1 reference

15 August 2017

D Wild

10

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 April 2002

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

86

1 reference

15 August 2017

8

1 reference

15 August 2017

1243-1249

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6600247

15 August 2017

0 references

cites work

Predicting the hematopoietic response to recombinant human erythropoietin (Epoetin alfa) in the treatment of the anemia of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375336

A risk-benefit assessment of epoetin in the management of anaemia associated with cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375336

Factors influencing quality of life in cancer patients: anemia and fatigue.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375336

Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: final report of a randomized, open-labelled, phase II trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375336

The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375336

Fatigue and the cancer experience: the state of the knowledge

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375336

The MOS 36-ltem Short-Form Health Survey (SF-36)

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375336

Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375336

Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375336

Recombinant human erythropoietin in the treatment of the anaemia of cancer

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375336

Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375336

Linking outcomes management to quality-of-life measurement.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375336

Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375336

The effect of subcutaneous recombinant human erythropoietin (r-HuEPO) on anemia in cancer patients receiving platinum-based chemotherapy

20 September 2018

1 reference

12 December 2020

Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors

1 reference

12 December 2020

Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy

1 reference

12 December 2020

Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: preliminary results of a randomized, open-labeled, phase II trial

1 reference

12 December 2020

Erythropoietin for anaemia in cancer patients

1 reference

12 December 2020

Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system

1 reference

12 December 2020

The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue

1 reference

12 December 2020

Recombinant human erythropoietin in the treatment of multiple myeloma-associated anemia

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6600247

1 reference

15 August 2017

1 reference

15 August 2017

1 reference